• Lucy McGeoch, Marinka Twilt, Leilani Famorca, Volodko Bakowsky, Lillian Barra, Susan M Benseler, David A Cabral, Simon Carette, Gerald P Cox, Navjot Dhindsa, Christine S Dipchand, Aurore Fifi-Mah, Michelle Goulet, Nader Khalidi, Majed M Khraishi, Patrick Liang, Nataliya Milman, Christian A Pineau, Heather N Reich, Nooshin Samadi, Kam Shojania, Regina Taylor-Gjevre, Tanveer E Towheed, Judith Trudeau, Michael Walsh, Elaine Yacyshyn, Christian Pagnoux, and Canadian Vasculitis Research Network.
• From the Department of Rheumatology, Mount Sinai Hospital, University of Toronto; Division of Nephrology, University Health Network, Toronto; Division of Rheumatology, Division of Respirology, and Department of Medicine and Department of Clinical Epidemiology and Biostatistics, McMaster University, St. Joseph's Healthcare, Hamilton; Division of Rheumatology, St. Joseph's Health Care, London; Langs Community Centre, Cambridge; Division of Rheumatology, the Ottawa Hospital/University of Ottawa, Ottawa; Division of Rheumatology and the Arthritis Program Research Group in Newmarket, Newmarket; Department of Medicine, Queen's University, Kingston, Ontario; Division of Pediatric Rheumatology, Alberta Children's Hospital, and Division of Rheumatology, University of Calgary, Calgary; Division of Rheumatology, University of Alberta, Edmonton, Alberta; Division of Rheumatology, QEII Health Sciences Centre and Dalhousie University; Division of Nephrology, Dalhousie University, Halifax, Nova Scotia; Division of Pediatric Rheumatology, BC Children's Hospital and University of British Columbia; Division of Rheumatology, Arthritis Research Canada, University of British Columbia, Vancouver, British Columbia; Section of Rheumatology, University of Manitoba, Arthritis Centre, Winnipeg, Manitoba; Division of Internal Medicine, Hôpital Du Sacré-Coeur; Division of Rheumatology, Lupus and Vasculitis clinic, McGill University, Montréal; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke; Division of Rheumatology, CHAU Hôtel-Dieu de Lévis, Université Laval, Quebec City, Québec; Division of Rheumatology, Memorial University of Newfoundland, Nexus Clinical Research, St. John's, Newfoundland; Division of Rheumatology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.L. McGeoch, MD, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, currently: Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK; M. Twilt,
• J Rheumatol. 2016 Jan 1; 43 (1): 97-120.

ObjectiveThe Canadian Vasculitis research network (CanVasc) is composed of physicians from different medical specialties and researchers with expertise in vasculitis. One of its aims is to develop recommendations for the diagnosis and management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada.MethodsDiagnostic and therapeutic questions were developed based on the results of a national needs assessment survey. A systematic review of existing non-Canadian recommendations and guidelines for the diagnosis and management of AAV and studies of AAV published after the 2009 European League Against Rheumatism/European Vasculitis Society recommendations (publication date: January 2009) until November 2014 was performed in the Medline database, Cochrane library, and main vasculitis conference proceedings. Quality of supporting evidence for each therapeutic recommendation was graded. The full working group as well as additional reviewers, including patients, reviewed the developed therapeutic recommendations and nontherapeutic statements using a modified 2-step Delphi technique and through discussion to reach consensus.ResultsNineteen recommendations and 17 statements addressing general AAV diagnosis and management were developed, as well as appendices for practical use, for rheumatologists, nephrologists, respirologists, general internists, and all other healthcare professionals more occasionally involved in the management of patients with AAV in community and academic practice settings.ConclusionThese recommendations were developed based on a synthesis of existing international guidelines, other published supporting evidence, and expert consensus considering the Canadian healthcare context, with the intention of promoting best practices and improving healthcare delivery for patients with AAV.

13 keywords...

hide…